Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy
about
Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolitesThe safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.Inhibition of STAT3 by Anticancer Drug BendamustineDetermination of Bendamustine in Human Plasma and Urine by LC-FL Methods: Application in a Drug MonitoringA Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events.Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.Bendamustine: role and evidence in lymphoma therapy, an overview.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateRegulatory aspects of human radiolabeled mass balance studies in oncology: concise review.Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
P2860
Q27011795-EAAA920A-0AC0-499D-89C3-3E216F7B566AQ33410064-42F9246A-668A-4092-86F2-80E5A5328E88Q33416982-F5527545-6AE3-4515-A64C-E9E09085E57DQ33877999-8F75AB28-59DD-493D-826C-E4A1D3826896Q36261308-1F4DA561-547A-455B-82FA-0F7FC2D4429CQ37059359-143A13CE-B6E5-407B-B144-D5276C957B1DQ37577645-C20D8B6E-947A-48B2-AD51-D60238794726Q38152510-FEC9C41D-E7E7-4FA4-BF83-9E38B716CBBBQ38158084-65D0598A-4C42-444A-8942-12C6374E349CQ38642648-7D0FE6E3-65BF-4C66-AF8F-A75D4F8FDF5DQ38836158-9039C978-16C5-4A3F-82CF-51F17A77ED6FQ38920650-985E540D-F7EB-4097-9C7C-65917FC8B437Q38947107-54B43E62-E294-4009-A1FC-AF3E983C3601Q39005626-8E5F3770-13B9-4582-A9E8-7C49D8F31012
P2860
Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacokinetics and excretion ...... apsed or refractory malignancy
@ast
Pharmacokinetics and excretion ...... apsed or refractory malignancy
@en
Pharmacokinetics and excretion ...... apsed or refractory malignancy
@nl
type
label
Pharmacokinetics and excretion ...... apsed or refractory malignancy
@ast
Pharmacokinetics and excretion ...... apsed or refractory malignancy
@en
Pharmacokinetics and excretion ...... apsed or refractory malignancy
@nl
prefLabel
Pharmacokinetics and excretion ...... apsed or refractory malignancy
@ast
Pharmacokinetics and excretion ...... apsed or refractory malignancy
@en
Pharmacokinetics and excretion ...... apsed or refractory malignancy
@nl
P2093
P2860
P1433
P1476
Pharmacokinetics and excretion ...... apsed or refractory malignancy
@en
P2093
Anne-Charlotte Dubbelman
Denise D'Andrea
Edward Hellriegel
Hilde Rosing
Jan H M Schellens
Jos H Beijnen
Mona Darwish
Philmore Robertson
P2860
P356
10.1007/S40268-012-0001-5
P577
2013-03-01T00:00:00Z